{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:07:13Z","timestamp":1790705233885,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T00:00:00Z","timestamp":1192579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetic Medicine"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Aims<\/jats:bold>\n                    \u2003The purpose of this study was to determine the relationship between subclinical hypothyroidism and prevalence of retinopathy and nephropathy, incident cardiovascular disease, and mortality in Type 2 diabetic patients without taking thyroid medication.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    \u2003Serum thyrotropin and free thyroxine concentrations were measured in 588 Type\u00a02 diabetic subjects in Taipei Veterans General Hospital, Taiwan. In a cross\u2010sectional study, we examined the prevalence of retinopathy and nephropathy. In a longitudinal study, we examined the risk of cardiovascular disease events, cardiovascular mortality and total mortality in the 4\u2010year follow\u2010up.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    \u2003In the cross\u2010sectional analysis, subclinical hypothyroidism was associated with a greater prevalence of diabetic nephropathy (odds ratio, 3.15 [95% CI, 1.48\u20136.69]) and did not show a high prevalence of diabetic retinopathy (odds ratio, 1.15 [95% CI, 0.59\u20132.26]) compare to euthyroid diabetics. During the 44.0\u00a0\u00b1\u00a07.4\u00a0months of follow\u2010up, 51 participants had cardiovascular events. The risk of cardiovascular events was significantly increased in Type\u00a02 diabetics with subclinical hypothyroidism after adjustment for age, sex, A1C, other standard cardiovascular risk factors and medication (hazard ratio, 2.93; 95% CI, 1.15\u20137.48;\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.024), but it became nonsignificant after additional adjustment for urinary albumin\u2010to\u2010creatinine ratio (hazard ratio, 2.06; 95% CI, 0.67\u20136.36;\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.211). The rates of cardiovascular\u2010related and total mortality did not significantly differ by thyroid status.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    \u2003Type\u00a02 diabetic patients with subclinical hypothyroidism are associated with an increased risk of nephropathy and cardiovascular events, but not with retinopathy. Our data suggest that the higher cardiovascular events in subclinical hypothyroidism with Type 2 diabetes may be mediated with nephropathy.\n                  <\/jats:p>","DOI":"10.1111\/j.1464-5491.2007.02270.x","type":"journal-article","created":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T18:54:25Z","timestamp":1192647265000},"page":"1336-1344","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type\u00a02 diabetic patients"],"prefix":"10.1111","volume":"24","author":[{"given":"H.\u2010S.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.\u2010E. J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.\u2010S.","family":"Jap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.\u2010A.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.\u2010L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.\u2010D.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,11,26]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-2-199807150-00020"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-4-200002150-00004"},{"key":"e_1_2_8_4_2","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jcem.86.10.7973","article-title":"TSH\u2010controlled 1\u2010thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo\u2010controlled trial (Basel Thyroid Study)","volume":"86","author":"Meier C","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-11-200212030-00011"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.4.8378"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107263450406"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.10.7959"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.10.7961"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.2.228"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1231"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6179.1678"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1995.tb00553.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199802)15:2<148::AID-DIA540>3.0.CO;2-H"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.19.s3.3.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1726-4901(09)70252-7"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8182"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180514"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.0014.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(01)80073-1"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/08860220500243338"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00169.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02236.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb01739.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032061"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.1.79"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.15.9.1216"},{"key":"e_1_2_8_28_2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1210\/jcem.86.3.7291","article-title":"Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo\u2010controlled study","volume":"86","author":"Monzani F","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/10507250050137743"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.6.5733"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.21.2460"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.21.2467"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102153440707"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01073-2"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.14.1291"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.11.1197"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400060077013"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-5491.2007.02270.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-5491.2007.02270.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T08:22:22Z","timestamp":1696926142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-5491.2007.02270.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,26]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1464-5491.2007.02270.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-5491.2007.02270.x","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,26]]},"assertion":[{"value":"2007-11-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}